An Open-label Combined Randomized Double-blind, Positive Control Clinical Trial in Subjects Aged 2 Months (Minimum 6 Weeks) and Above to Preliminary Evaluate the Safety and Immunogenicity of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
Latest Information Update: 27 Dec 2024
At a glance
- Drugs Pneumococcal 13-valent vaccine conjugate Sinovac Biotech (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Sinovac Biotech
- 20 Dec 2024 Status changed from recruiting to completed.
- 24 May 2024 Planned End Date changed from 30 Dec 2023 to 6 Jun 2024.
- 24 May 2024 Planned primary completion date changed from 30 Dec 2023 to 6 Jun 2024.